Effect of Acute Endurance Exercise on the Production of FGF21 and Follistatin in Patients With Hepatocellular Carcinoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Exercise.
- Who it may be relevant to
- Registry conditions: Cirrhosis With Hepatocellular Carcinoma. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The main purpose of the study is to characterize the production of hepatokines (FGF21 and Follistatin) in response to a submaximal exercise on an ergocycle, in patients with hepatocellular carcinoma. The effect of exercise on hepatokines and metabolites production in liver cancer patients is not known. Studying this production could help to provide relevant recommendations for training programming in these patients.
Interventions
- Other Exercise
30-minutes exercise on a bicycle with heart rate monitor and gas exchange analyzer.
Primary outcome measures
- Systemic hepatokines rates (FGF-21 and follistatin) [Time frame: Baseline (pre-exercise), immediately after exercise, 1 hour after the end of exercise]
Secondary outcome measures (1)
- Muscle pain assessment [Time frame: Baseline (pre-exercise), immediately after exercise, 1 hour after the end of exercise]
Eligibility criteria
Inclusion criteria
- Hepatocellular carcinoma developed on cirrhosis
- Cirrhosis of any etiology, defined by a liver elasticity measurement >15kPa or a history of cirrhosis decompensation
- Hepatocellular carcinoma with indication for treatment by immunotherapy or chemoembolization
- Child-Pugh scores A and B7
- WHO score ≤ 2
- Affiliation to french national social security system
Exclusion criteria
- Hepatic encephalopathy grade II or higher
- Bone metastasis
- Surgery performed within 30 days prior to inclusion visit
- Liver transplant
- Muscle injury within 3 months of inclusion
- Pregnant or breast-feeding women
- Patients under legal protection (guardianship, curatorship, safeguard of justice)
- Participation in another clinical trial within 10 days of inclusion
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Other
Study locations
France · 2 centers
- Chu Estaing Medecine Digestive Et Hepatobiliaire — Clermont-Ferrand
- CHU de Clermont-Ferrand — Clermont-Ferrand
Identifiers
NCT: NCT07189624 · RBHP 2024 ABERGEL